<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942487</url>
  </required_header>
  <id_info>
    <org_study_id>MeRo/04/Neb-LVD/003</org_study_id>
    <nct_id>NCT00942487</nct_id>
  </id_info>
  <brief_title>Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol</brief_title>
  <acronym>ENESYS</acronym>
  <official_title>Effects of NEbivolol on Subclinical Left Ventricular dYSfunction. A Comparative Study Against Metoprolol. The ENESYS Study. A Phase 3, Randomised, Parallel, Active-controlled, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berlin-Chemie Menarini</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berlin-Chemie Menarini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Summary:&#xD;
&#xD;
        -  Study title: Effects of Nebivolol on subclinical left ventricular dysfunction. A&#xD;
           comparative study against Metoprolol. (ENESYS study)&#xD;
&#xD;
        -  Study phase: 3&#xD;
&#xD;
        -  Study design (parallel, cross-over, etc.), randomisation and blinding procedures, type&#xD;
           of control (placebo or active): randomised, parallel, active-controlled, open label&#xD;
&#xD;
        -  Study treatment(s)/drug(s): Nebivolol versus Metoprolol&#xD;
&#xD;
        -  Patients:&#xD;
&#xD;
             -  characteristics: patients with hypertension and left ventricular hypertrophy&#xD;
&#xD;
             -  planned total number: 50&#xD;
&#xD;
        -  Study duration:&#xD;
&#xD;
             -  total enrolment period (months): 18&#xD;
&#xD;
             -  treatment period (months): 6&#xD;
&#xD;
             -  follow up period (months): 6&#xD;
&#xD;
        -  Total study duration (months): 24&#xD;
&#xD;
             -  Number of Centres: 1&#xD;
&#xD;
             -  Country(ies): Romania (RO)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES&#xD;
&#xD;
        1. PRIMARY:&#xD;
&#xD;
             -  Longitudinal myocardial velocities at rest (assessed by tissue Doppler&#xD;
                echocardiography)&#xD;
&#xD;
             -  Systolic functional reserve (calculated as the absolute and relative increase of&#xD;
                the myocardial systolic velocities at peak stress from rest)&#xD;
&#xD;
             -  Brain natriuretic peptide (BNP, NT-pro BNP) after a 6-months period of treatment&#xD;
                with nebivolol versus metoprolol. An improvement of more than 20% of the myocardial&#xD;
                resting velocities of systolic functional reserve is considered to be clinically&#xD;
                relevant. The working hypothesis is that the improvement of subclinical left&#xD;
                ventricular dysfunction after 6 months of treatment is going to be greater in&#xD;
                patients who receive nebivolol than in those who receive metoprolol.&#xD;
&#xD;
        2. SECONDARY:&#xD;
&#xD;
             -  Global systolic function (ejection fraction)&#xD;
&#xD;
             -  Radial myocardial velocities&#xD;
&#xD;
             -  Right ventricular function&#xD;
&#xD;
             -  Global diastolic function&#xD;
&#xD;
             -  Left ventricular mass index&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of: longitudinal myocardial velocities at rest (assessed by TDE), systolic functional reserve (calculated as the absolute and relative increase of the myocardial systolic velocities at peak stress from rest), NT-proBNP</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global systolic function (ejection fraction)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial myocardial velocities</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global diastolic function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass index</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebilet</intervention_name>
    <description>Trade-mark: NebiletÂ® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corvitol</intervention_name>
    <description>Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration</description>
    <arm_group_label>Metoprolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 18 years or older, men and women, hospitalized and outpatients&#xD;
&#xD;
          -  with a history of primary arterial hypertension&#xD;
&#xD;
          -  with a daytime ambulatory blood pressure &gt;140 and/or &gt;90 mm Hg&#xD;
&#xD;
          -  with left ventricular hypertrophy: LVMI &gt; 125 g/m2 for men, and &gt; 110 g/m2 for women,&#xD;
             by Devereux formula, as recommended by the ESH-ESC guidelines (14)&#xD;
&#xD;
          -  in sinus rhythm&#xD;
&#xD;
          -  consented, by signing the Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe arterial hypertension (systolic blood pressure &gt; 180 mm Hg and/or diastolic&#xD;
             blood pressure &gt; 110 mm Hg)&#xD;
&#xD;
          -  Any history of coronary heart disease (stable angina, acute coronary syndromes,&#xD;
             myocardial infarction)&#xD;
&#xD;
          -  Any history of cerebrovascular disease&#xD;
&#xD;
          -  Renal impairment (creatinine &gt; 1.5 mg% for men, &gt; 1.4 mg% for women)&#xD;
&#xD;
          -  Left ventricular global systolic dysfunction (EF &lt; 45%)&#xD;
&#xD;
          -  More than mild valvar (mitral or aortic) regurgitation&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Pericarditis&#xD;
&#xD;
          -  Cor pulmonale&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Any significant co-morbidities&#xD;
&#xD;
          -  Contraindication to beta-blocker therapy&#xD;
&#xD;
          -  Concomitant treatment with other beta-blockers&#xD;
&#xD;
          -  Participation to another investigational study in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dragos VINEREANU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University and Emergency Hospital Bucharest, Romania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University and Emergency Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 19, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2009</study_first_posted>
  <last_update_submitted>July 20, 2009</last_update_submitted>
  <last_update_submitted_qc>July 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Dragos VINEREANU</name_title>
    <organization>University and Emergency Hospital of Bucharest</organization>
  </responsible_party>
  <keyword>arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

